Fig. 1: T-cell infiltration improves CD3xTRP1 bsAb therapy in B16F10 melanoma.
From: T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
CD3xTRP1 treatment in WT or CXCR3 KO mice bearing B16F10 mouse melanoma tumors. a Treatment schedule. b Kaplan-Meier survival graph for indicated groups. Numbers indicate the fraction of mice alive at the end of the experiment. c Frequencies of intratumoral CD8 and CD4 T cells 4 days after CD3xTRP1 treatment. CD3xTRP1 treatment in combination with adoptive transfer of OT-1 cells and OVA peptide vaccination in mice bearing B16F10 tumors. d Treatment schedule. e Kaplan-Meier survival graph for indicated groups. Numbers indicate the fraction of mice alive at the end of the experiment. f Frequencies of intratumoral total CD8 and OT-1 T cells in B16F10 tumors at day 19, according to the schedule in Supplementary Fig. 2b. Data represented as mean ± SEM (c, f). c (WT untreated (n = 4), WT bsAb (n = 4), CXCR3 KO untreated (n = 4), CXCR3 KO bsAb (n = 5)), f (Untreated (n = 5), BsAb (n = 6), OT-1 + OVA vacc (n = 5), OT-1 + OVA vacc + bsAb (n = 6)). Statistics of survival were calculated using Mantel-Cox Log-Rank tests (b, e) and T-cell frequencies were compared using one-way ANOVA tests and Tukey’s post-hoc analyses comparing all groups (c, f). Source data are provided as a Source Data file.
